Bayer licenses PET tracer research from Hamamatsu
Bayer Schering Pharma and Hamamatsu Photonics have signed a licensing agreement for the use of new substances in the field of molecular imaging for cancer.
Under the terms of the agreement, Bayer has acquired the global exclusive rights for research, development and commercialization of a group of molecules that specifically bind to malignant tumor cells from the Shizoka, Japan-based Hamamatsu. In combination with PET, these tracers could potentially improve the diagnosis of a variety of cancers, the Berlin-Wedding, Germany-based Bayer said.
The tracers are labeled with a short-life radionuclide for PET imaging. In contrast to the presently common procedures in PET imaging of cancer, these tracers could help to possibly better differentiate malignant tumors from benign tissue alterations and to allow a more precise staging of the cancer, according to Bayer.
Under the terms of the agreement, Bayer has acquired the global exclusive rights for research, development and commercialization of a group of molecules that specifically bind to malignant tumor cells from the Shizoka, Japan-based Hamamatsu. In combination with PET, these tracers could potentially improve the diagnosis of a variety of cancers, the Berlin-Wedding, Germany-based Bayer said.
The tracers are labeled with a short-life radionuclide for PET imaging. In contrast to the presently common procedures in PET imaging of cancer, these tracers could help to possibly better differentiate malignant tumors from benign tissue alterations and to allow a more precise staging of the cancer, according to Bayer.